Oridonin inhibits Hela cell proliferation via downregulation of glutathione metabolism: a new insight from metabolomics
Journal of Pharmacy and Pharmacology · 2023
DOI: 10.1093/jpp/rgad025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2023. Verfasst von Weijia Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of International Medical Services (IMS), Beijing Tiantan Hospital of Capital Medical University, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Diterpenes, Kaurane. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province.
Abstract (Originalsprache)
Objectives
This study aims to elucidate Oridonin' s inhibitory mechanism to cervical cancer using metabolomics methods and pharmacological assays.
Methods
Network pharmacology and KEGG pathway analysis are used to identify overlapped targets and involved metabolic pathways. UPLC-MS/MS metabolomics analysis is used to determine altered metabolites after Oridonin treatment. Other bioassays are also employed to uncover the changes in critical molecules that are highly related to altered metabolites. Key findings Seventy-five overlapped targets are identified between Oridonin and cervical cancer. Twenty-one metabolites involved in tricarboxylic acid cycle glutathione metabolism, branched-chain amino acid metabolism and so on changes significantly after Oridonin treatment. Oridonin treatment significantly reduces the content of cysteine and inhibit the catalytic activity of glutamine–cysteine ligase subunit, a rate-limiting enzyme for the synthesis of glutathione. As a result, the content of glutathione is also reduced. The antioxidant enzyme glutathione peroxidase 4 which uses glutathione as a cofactor, is inactivated, resulting in a burst release of reactive oxygen species. The ATP content is also significantly reduced in Hela cells after Oridonin treatment.
Conclusions
This study finds that Oridonin treatment induces Hela cell apoptosis possibly via inhibition of the glutathione metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of International Medical Services (IMS), Beijing Tiantan Hospital of Capital Medical University, Beijing, People's Republic of China.
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, People's Republic of China.
ORCID-Profile: Weijia Wang, Nan Zhang
Förderung
- Natural Science Foundation of Henan Province
Zitieren
APA
Wang, W., & Zhang, N. (2023). Oridonin inhibits Hela cell proliferation via downregulation of glutathione metabolism: a new insight from metabolomics. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad025
Vancouver
Wang W, Zhang N. Oridonin inhibits Hela cell proliferation via downregulation of glutathione metabolism: a new insight from metabolomics. Journal of Pharmacy and Pharmacology. 2023. doi:10.1093/jpp/rgad025
BibTeX
@article{Wang2023,
author = {Wang, Weijia and Zhang, Nan},
title = {Oridonin inhibits Hela cell proliferation via downregulation of glutathione metabolism: a new insight from metabolomics},
journal = {Journal of Pharmacy and Pharmacology},
year = {2023},
doi = {10.1093/jpp/rgad025}
}
EUVIMED